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The canine parvovirus (CPV) infection is a highly contagious and serious enteric
disease of dogs with high fatality rate. The present study was taken up to characterize the
full-length viral polypeptide 2 (VP2) gene of CPV of Indian origin along with the
commercially available vaccines. The faecal samples from parvovirus suspected dogs
were collected from various states of India for screening by PCR assay and 66.29% of
samples were found positive. Six CPV-2a, three CPV-2b, and one CPV-2c types were
identiﬁed by sequence analysis. Several unique and existing mutations have been
noticed in CPV types analyzed indicating emergence of newer variants of CPV in India.
The phylogenetic analysis revealed that all the ﬁeld CPV types were grouped in
different subclades within two main clades, but away from the commercial vaccine
strains. CPV-2b and CPV-2c types with unique mutations were found to be establishing
in India apart from the prevailing CPV-2a type. Mutations and the positive selection of
the mutants were found to be the major mechanism of emergence and evolution of
parvovirus. Therefore, the incorporation of local strain in the vaccine formulation may
be considered for effective control of CPV infections in India.
Keywords: canine parvovirus (CPV), mutation, phylogenetic analysis,
polymerase chain reaction (PCR), sequencing
Introduction
Canine parvovirus (CPV) infection is highly contagious and a serious
enteric disease of dogs with high fatality rate. It is a member of the species
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Carnivore protoparvovirus 1, genus Protoparvovirus of the family Parvoviridae,
which also includes feline panleukopenia virus (FPV) and mink enteritis virus.
CPV caused by CPV-2 is considered as canine-speciﬁc variant of the FPV that
emerged as a novel pathogen in the late 1970s as a consequence of an interspecies
jump from other carnivores to dogs and spread rapidly worldwide [1]. However, by
the end of 1980, CPV-2 was completely replaced globally in dogs by a genetic and
antigenic variant termed CPV-2a with Met87Leu, Ile101Thr, Ala300Gly,
Asp305Tyr, Asn375Asp, and Val555Ile variations [2]. Subsequently, viral poly-
peptide 2 (VP2) residue 426, changed from Asn426Asp and then from Asp426Glu
in the so-called CPV-2b and CPV-2c antigenic variant strains, respectively.
However, as the CPV-2b and CPV-2c antigenic strains differ from CPV-2a at
only one position (VP2 residue 426), they are nowconsidered to be variants ofCPV-
2a rather than distinct subtypes, as are all of the CPVs circulating worldwide today
[3–13]. During early 1990s in German CPV isolates, an additional amino acid
difference was observed in CPV-2a and CPV-2b at 297th amino acid position
(Ser297Ala) and the mutants were designated as New CPV-2a/2b [14]. CPV and
FPV are two closely related viruses, causing disease in respective hosts, but new
variants of CPVs have acquired the feline host range allowing them to infect both
cats and dogs [15–17], whereas the original CPV-2 does not replicate in cats.
Ampliﬁcation of VP2 gene and subsequent sequencing of the PCR products,
where many important informative amino acids lies would give deﬁnitive
antigenic and genetic difference between the original CPV-2, its variants, and
the vaccine strains [18]. As mutation and recombination in VP2 gene inﬂuence the
host range and afﬁnity of receptor binding [19], it becomes important to sequence
full-length VP2 encoding gene for better and precise identiﬁcation of emerging
strains, their relationship with vaccine strains, and also to understand the evolu-
tionary pattern of CPV strains in the ﬁeld.
As no such study involving full-length VP2 encoding gene analysis had
been documented with CPV isolates of Indian origin, the present study was
undertaken for a detailed genetic analysis of full-length VP2 gene sequences of
CPV types isolated from domestic dogs covering all the ﬁve geographical regions
of India. The full-length VP2 encoding gene of the CPV types present in the
commercial vaccines available in India were also analyzed.
Materials and Methods
Sample collection and laboratory processing
A total of 89 faecal samples/rectal swabs from CPV suspected diarrhoeic
dogs of different age group were collected from different states covering all the
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ﬁve regions of India (Western, Eastern, Northern, Southern, and Central) over one
year period (December 2013 to December 2014) as detailed in Table I. The faecal
samples/rectal swabs were emulsiﬁed in 1 ml of 0.1 M PBS of pH 7.4, stored at
4 °C, and transported to the laboratory under refrigeration. The emulsions were
centrifuged at 10,000 rpm for 15 min at 4 °C and the supernatant was passed
through 0.45 μmmembrane ﬁlter (Millipore, CA, USA). The ﬁltrate was collected
and stored at −40 °C until further use.
Screening of samples by polymerase chain reaction
Total nucleic acid from all the clinical specimens was extracted by boiling-
lysis method at 96 °C for 10 min followed by chilling immediately in crushed ice.
Following high speed centrifugation, the supernatants were diluted at 1:10 in
milliQ water to reduce residual inhibitors of DNA polymerase activity [18, 20].
The extracted template DNA was stored at −40 °C until further use and was
screened for the presence of CPV using Hfor/Hrev primer pair listed in Table II,
which ampliﬁes a 630 bp fragment of the VP2 gene encoding capsid protein [21].
The DNA prepared from CPV-2 (Strain C154, Intervet India Pvt. Ltd., India)/
CPV-2b vaccine strain (Fort Dodge Animal Health Inc., USA) maintained in the
Department of Veterinary Microbiology, Rajiv Gandhi Institute of Veterinary
Education and Research, Puducherry, India, was used as positive control in the
PCR assay.
The PCR-ampliﬁcation of VP2 capsid protein gene was carried out using
100 ng template DNA, 5 μl 10× PCR buffer, 2 mMMgCl2, 1 μl of 10 mM dNTPs,
10 μMof forward and reverse primers, 2U of Taq DNA Polymerase (New England
Biolabs, MA, USA) and the volume was made up to 50 μl with Nuclease Free
Table I. Details of sample collection and the results
S. No. Regions State/Union territory Place Clinical samples Positive by PCR
1. Western Maharashtra Mumbai 5 3
Nagpur 14 10
2. Eastern West Bengal Kolkata 15 9
Sikkim Gangtok 4 3
3. Northern Punjab Ludhiana 9 8
Gurdaspur 9 4
Uttar Pradesh Mathura 9 5
4. Southern Kerala Thrissur 7 4
Puducherry Puducherry 13 10
5. Central Madhya Pradesh Jabalpur 4 3
Total 89 59 (66.29%)
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water. The PCR ampliﬁcation consisted of initial denaturation at 95 °C for 5 min
followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s,
and extension at 70 °C for 1 min, followed by a ﬁnal extension at 70 °C for 10 min.
The PCR ampliﬁed products were resolved on 1.5% agarose gel containing
ethidium bromide in Tris acetate EDTA (TAE) buffer and visualized under UV
transilluminator (Syngene, UK).
Virus isolation
Virus isolation was carried out as per the procedure recommended by
Hirayama et al. [24]. Twenty-four PCR positive samples representing the diverse
geographical locations of India were randomly selected and subjected for isolation
of virus in A-72 cell line maintained in RPMI-1640 media (Sigma-Aldrich,
St. Louis, MO, USA). The clinical samples were ﬁltered and used for virus
isolation in A-72 cell line. The infected monolayers were harvested third day post
inoculation (with or without cytopathic effect) by three cycles of alternative
freezing, thawing, and stored at−40 °C until further use. After three blind passages
in A-72 cell line, DNA released from the cell culture ﬂuids were conﬁrmed for the
presence of the virus by PCR ampliﬁcation using Hfor/Hrev primer pair.
Genotyping of CPV samples/isolates
Seven randomly selected PCR (Hfor/Hrev) positive clinical samples and three
cell culture isolates were subjected to another four individual PCR assays using
four sets of overlapping sequencing primer pairs listed in Table II following the
same protocol as detailed earlier. The full-length VP2 gene of the CPV vaccine
strains available in India was also ampliﬁed. The PCR-ampliﬁed products were
excised from the gel and extracted using gel extraction kit (Qiagen, Hilden,
Germany). The four overlapping PCR products of VP2 gene (for each sample/
isolate) were sequenced for both the strands of DNA (5′-3′ and 3′-5′) and aligned
to determine their nucleotide/amino acid variations in VP2 gene. The sequencing
was carried out using automated DNA sequencer (Applied Biosystems Inc., CA,
USA) at Euroﬁns Genomics Private Limited, Bengaluru, India. The sequence
chromatogram was visualized in BioEdit v 7.0.5 analysis software (Isis Thera-
peutics, Carlsbad, CA, USA). Nucleotide Blast was performed with the obtained
sequences using the NCBI nucleotide database (http://www.ncbi.nlm.nih.gov/
Blast) to conﬁrm the genus speciﬁcity to CPV. VP2 gene sequences of FPV, CPV-
2, CPV-2a, CPV-2b, and CPV-2c from different part of the world were retrieved
from the NCBI nucleotide database and multiple sequence alignment was
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performed using the Clustal W algorithm in MEGA5 software [25]. The aligned
sequences of VP2 genes of 10 CPV types under this study were submitted in
Genbank for allotment of accession numbers.
Phylogenetic analysis
The CPV sequences obtained in this study, the sequences of CPV-2/2b
vaccine strains available in India and the sequences retrieved from GenBank were
aligned and evolutionary history was inferred employing the maximum-likelihood
method [26] based on the Tamura Nei parameter model implemented in MEGA 5
program. The branch lengths were measured in terms of the number of substitu-
tions per site. Bootstrap test (1,000 replicates) was done to evaluate the conﬁdence
level of branching in the phylogenetic tree.
Results
Polymerase chain reaction
Of the total 89 faecal samples collected from CPV suspected dogs,
59 samples (66.29%) were found positive for CPV by PCR assay (Table I).
Higher incidence of CPV infection was observed in pups below six months of age
(74.58%).
Virus isolation
In A-72 cell culture, mild cytopathic effect in the form of rounding,
increased granularity and detached cells could be seen 3–4 days post infection
for 12 dog samples at third passage level. The cryolysates were also conﬁrmed as
positive for CPV by PCR. The virus in the remaining samples failed to grow in
A-72 cell line.
Sequencing and BLAST analysis
Upon Basic Local Alignment Search Tool (BLAST) analysis, the speciﬁcity
of the sequences of full-length VP2 gene of CPV obtained from 10 faecal samples/
cryolysates was found to be maximally identical (99–100%) with VP2 gene
sequences of CPV strains available in the GenBank. The sequencing results
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revealed six sequences obtained in this study (KLD3, MD1, SD2, WBD4, NAG3,
and WBD1) as New CPV-2a, 3 sequences (KD4, KD5, and LD4) as New CPV-2b
and 1 sequence (JD3) as CPV-2c (Supplementary Table I). The present study
reports the isolation of CPV-2c in cell culture for the ﬁrst time in India.
Nucleotide sequence accession numbers and mutations
The GenBank accession numbers for the CPV strains were depicted in
Table III. Additionally, several non-synonymous (Table III) and synonymous
(Supplementary Table II) mutations were also noticed in the CPV sequences
analyzed in this study.
Phylogenetic analysis
All the CPV types sequenced in this study were distributed in three different
monophyletic clades (Figure 1). All the six CPV-2a and interestingly the two
CPV-2b types (KD4 and KD5, Kolkata) showed common ancestor with CPV-2a
type from China (CPV-2a/CHINA/2011/JQ268283). Two CPV-2a types (KLD3,
Thrissur and NAG3, Nagpur) showed immediate relationship with Uruguayan and
Chinese CPV-2a isolates and the other four CPV-2a types (WBD1 and WBD4,
Kolkata; MD1, Mumbai and SD2, Gangtok) showed independent evolution. The
two CPV-2b types (KD4 and KD5, Kolkata) formed a separate subclade within the
same CPV-2a clade and were related to a recent Chinese CPV-2b isolate (CPV-2b/
CHINA/2013/KR002799). However, the other CPV-2b type (LD4, Ludhiana) was
arranged in a different clade (CPV-2b clade) and showed ancestral relationship
with older CPV-2b types from USA (CPV-2b/USA/1998/EU659121 and CPV-2b/
USA/1998/AY742936). A commercial vaccine strain (CPV-2b) Duramune Max5
(Fort Dodge) also clustered in this group. The single CPV-2c type JD3 (Jabalpur)
formed a different subclade in this clade and was ancestrally related to the CPV-2c
isolates from Italy and Uruguay (CPV-2c/ITALY/2000/FJ222821 and CPV-2c/
URUGUAY/2011/KM457142). All the CPV-2 containing commercial vaccines
like Vanguard (Pﬁzer), CaniShot K5 (Intas), Biocan (Bioveta), and Canigen
(Virbac) were closely clustered in CPV-2 clade along with prototype CPV-2 strain
(M38245) from USA.
Discussion
The result of the PCR screening assay in dogs was in concordance with
the results obtained by Srinivas et al. [27] and Mukhopadhyay et al. [28].
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Figure 1. Maximum likelihood tree depicting phylogenetic relationship among CPV isolates.
Parvoviruses obtained from dogs sequenced in this study are shownwith solid circles and the vaccine
strains are shown with solid triangles. Bootstrap values are shown next to the branches in the
phylogenetic tree
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The disease was predominantly noticed in dogs between 0- and 6-month age group
(74.58%) as also reported by other authors [29, 30]. It is well known that increased
intestinal epithelial turnover caused by changes in the microﬂora, diet (weaning),
and diminishing maternal antibody level are the predisposing factors to CPV
infection in pups [31].
The present study, involving the full-length sequence analysis of VP2 gene
for the ﬁrst time in Indian CPV isolates, conﬁrmed that the New CPV-2b type (Ala
297 & Asp 426) had also established in diverse dog population in India along with
the prevalent New CPV-2a type (Ala 297 and Asn 426). The presence of CPV-2c
type in India was also identiﬁed and conﬁrmed by the study. Nandi et al. [32]
reported presence of CPV-2c type from North India, but it was not until 2015
(present study) that CPV-2c type was ﬁrst isolated in India (Jabalpur, Madhya
Pradesh, and Central India), which clearly indicated slow but steady spread of
CPV-2c type in Indian dog population. It is a matter of concern as CPV-2c type is
often associated with severe infections even in adult dogs regardless of their
vaccination status [33] and replaces the other predominant CPV types within few
years of its emergence [34–36].
Two unique amino acid changes Asp3Glu caused by a T→G transversion
in the third nucleotide of the corresponding codon (nt 9 of the VP2 gene) and
Val6Ala caused by a T→C transition in the second nucleotide of the corre-
sponding codon (nt 17 of the VP2 gene) were noticed in the CPV-2c (JD3) type
isolated in the present study. These mutations were also never reported in any
other CPV-2c types sequenced to date. Very recently, Wang et al. [37] reported
isolation of a novel Ala5Gly mutant of CPV-2c types in China. Although the
functional impact of these mutations was yet to be ascertained, the present
study, however, conﬁrmed that this particular stretch of the VP2 gene of
CPV-2c type was in the midst of an active evolution process in India
and China.
In KD5, a CPV-2b type from Kolkata, two interesting and unique amino
acid changes Leu87Met (caused by a T→A transversion in the ﬁrst nucleotide of
the corresponding codon; nt 259 of the VP2 gene) and Thr101Ile (caused by a
CC→TT double transition in the second and third nucleotide of the corresponding
codon; nt 302 and 303 of the VP2 gene) were identiﬁed. Four amino acid changes
at 87, 101, 300, and 305 positions of VP2 residues differentiate the CPV-2a type
and its variants from the prototype CPV-2. Mutations at these four amino acid
positions inﬂuence infection by altering binding to the canine transferrin receptor
(TfR), the host cell attachment protein. Additionally, these four mutations have
been shown to alter antibody binding, as they cluster to a position on the capsid
surface where an antigenic site overlaps with receptor binding site. Therefore, this
CPV-2b type (KD5), showing mutations in two (87 and 101) out of the four
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differentiating amino acids might be either mutating back to CPV-2 or in a process
of recombination between the vaccine strain (containing CPV-2 strain) and the
ﬁeld strain. Mochizuki et al. [38] provided the ﬁrst documentation of clear
evidence of recombination events between CPV-2 (Vaccine) and CPV-2a/
CPV-2b ﬁeld viruses in dogs vaccinated with live combined vaccine containing
CPV-2.
Among the other non-synonymous mutations, the amino acid change
Phe267Tyr was observed in all the six CPV-2a types (KLD3, SD2, MD1, NAG3,
WBD1, and WBD4) and the two CPV-2b types (KD4 and KD5) of dogs. This
mutation was also reported previously in CPV-2a and CPV-2b types [28, 39–41].
The amino acid residue 267 is not exposed on the capsid surface and substitutions
in this position may not affect the antigenicity of the virus [42]. All the CPV types
analyzed in this study also showed amino acid change Ser297Ala, which was
under strong positive selection pressure and played important role in host cell
adaption [43, 44].
Similarly the amino acid change Tyr324Ile was noticed in most of the
sequences analyzed in this study. Similar codon changes at amino acid positions
324 were also reported in the CPVs isolated in different countries [28, 41, 44–46].
Horiuchi et al. [47] revealed that the residue 324 was prone to strong positive
selection in all carnivorous CPV isolates. The residue 324 was adjacent to residue
323, responsible for TfR binding, and together with residue 93, determined the
canine host range. Therefore, mutation at amino acid residue 324 is likely to have
an impact on the parvovirus host range. It was also documented that
Ile-324 substitution was in regions of potentially important antigenic epitopes
and this substitution might have a direct inﬂuence on viral biology [48].
Interestingly, the frequency of CPVs carrying mutations at 267Tyr and 324Ile
residues had increased enormously and had reached a high prevalence among
Indian CPV isolates only since 2012–13 [27, 28, 44].
The next important amino acid change Thr440Ala was observed in two
CPV-2a types (KLD3 and NAG3) and two CPV-2b types (KD4 and KD5). The
amino acid residue 440 is important because it is located at the top of the 3-fold
spike (GH loop) of the VP2 protein on the surface of the capsid, the main antigenic
site of the virus [49, 50]. This residue was undergoing positive selection for the
past few years and had evolved independently in different populations, which
explained its world-wide mutation in unrelated CPV-2 populations [51]. Similar
codon change at amino acid position 440 was also reported in CPVs isolated in
different countries [28, 44, 52]. Mutation at amino acid residue 440 would,
therefore, result in emergence of further antigenic variants. Decaro et al. [53]
reported an Asp434Val mutation in certain Italian CPV types; but in the present
study, a CPV-2a type (NAG3) isolated from Nagpur showed a different mutation
Acta Microbiologica et Immunologica Hungarica 63, 2016
VP2 GENE ANALYSIS OF CANINE PARVOVIRUS IN INDIA 421
in the same amino acid residue (Asp434Asn). In addition, 14 synonymous
substitutions were also observed in the sequences under study.
No indication of separation of lineage based on geographical location could
be identiﬁed in the phylogenetic study and most CPV types were found to have
evolved independently. The interesting clustering of two CPV-2b (KD4 and KD5)
types along with recently isolated Chinese CPV-2b strains (KR002799) in the
CPV-2a clade provides ample proof of continuous evolution of CPVs. The
commercially available vaccine strains (CPV-2) were clustered in CPV-2 clade
away from most of the CPV ﬁeld types sequenced in this study. In fact, Indian
CPVs in the ﬁeld are moving away from the commercial vaccine strains as is
evident from the phylogenetic tree.
Therefore, as per the present study, mutations and the positive selection of
the mutants was found to be the major mechanism of continuous emergence and
the evolution of CPVs in India. This study involving full-length analysis of
VP2 gene, therefore, deﬁnitely added valuable information to the evolution of
CPVs in India. CPV-2a and CPV-2b variants have established in different
geographical regions of India and CPV-2c also is in the process of establishing
in the ﬁeld. Constant monitoring and surveillance of larger areas to identify and
analyze newer CPV types and variants has to be continued. Vaccination with the
conventional CPV-2 based vaccines result in evolutionary pressure on the ﬁeld
viruses leading to emergence of newer strains/variants. These newer strains/
variants can spread in immunized dogs by breaking through the vaccine induced
defence especially in passively immune new born pups. Therefore, time has come
to have a close look on CPV vaccine policy in India and considering the current
epidemiological scenario, incorporation of prevailing local strains may be the need
of the hour.
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